ClinicalTrials.gg
Not yet recruitingNCT07749430Updated Aug 6, 2026

A Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus

An Early Phase 1 interventional study of ACG102 Injection in Refractory Active Systemic Lupus Erythematosus, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Planned enrollment
5th of 11
13 · median 12
Started
2026
with 4 others
Phase 1
7 of 11
5 open now
Registered
11th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 7 in phase 1, and was the 11th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ACG102 administered via intravenous injection in patients with refractory active systemic lupus erythematosus (SLE)

Read the detailed description

A first-in-human, open label study to evaluate safety and tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of multiple ascending dose ACG102 intravenously administered to adult participants with refractory active systemic lupus erythematosus (SLE)

03

Conditions studied

  • Refractory Active Systemic Lupus Erythematosus

Keywords

  • ACG102-001
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. ≥18 years of age at time of .
  2. Diagnosis of systemic lupus erythematosus (SLE) fulfilling the 2019 EULAR/ACR classification criteria.
  3. active disease defined as inadequate response to, or relapse following, standard of care (SoC) therapy.
  4. Patients on a stable dose of SoC for at least 4 weeks prior to enrollment.
  5. Sufficient organ function as defined by the protocol.

Key Exclusion Criteria:

  1. Active severe infection, including tuberculosis.
  2. Severe hypogammaglobulinemia or IgA deficiency.
  3. Active hepatitis or history of severe liver disease.
  4. Severe cardiovascular diseases.
  5. History of cancer within the past 5 years (with exceptions per protocol).
  6. Receipt of B-cell-targeted therapies or other biologic therapies within the defined washout window prior to enrollment.
  7. History of organ transplantation, bone marrow transplantation, or hematopoietic stem cell transplantation.
  8. Known allergy to any active or inactive component of the study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    ACG102

    Multiple escalating intravenous doses of ACG102 administered on pre-specified days to adult patients with refractory active SLE. Dose levels and schedules may be adjusted based on emerging safety, tolerability, and PK/PD data, followed by a safety and efficacy follow-up period.

    Drug: ACG102 Injection

Interventions

  • DrugACG102 Injection

    All enrolled participants will receive multiple intravenous infusions of ACG102 at the dose level assigned to their cohort. Dose levels and dosing schedules may be adjusted based on emerging safety, tolerability, and PK/PD data.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Number and proportion of participants experiencing DLT. A DLT is defined as any treatment-emergent adverse event (TEAE) occurring within the 21-day DLT evaluation period post-infusion that meets protocol-specified criteria, graded per NCI CTCAE v5.0 and ASTCT consensus criteria for CRS and ICANS, and is considered at least possibly related to the study intervention

    Time frame: Within 21 days after first dose

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Percentage of participants experiencing TEAEs, SAEs, and Adverse Events of Special Interest (AESIs) graded per NCI CTCAE v5.0 and ASTCT consensus criteria

    Time frame: From first dose through Week 52

  3. Incidence of Treatment-Emergent Clinical Laboratory Abnormalities

    Number of participants with clinically significant shifts from baseline in safety laboratory assessments (hematology, liver enzymes, coagulation, and vital sign)

    Time frame: Up to 52 weeks post first dose

Secondary outcomes

  1. Change from baseline in SLE disease activity scores

    Change from baseline will be calculated as the score at each post-baseline visit minus the score at baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Time frame: baseline and up to Week 52 post first dose

  2. Change from Baseline in BILAG-2004 Score

    Change from baseline will be calculated as the total score at each post-baseline visit minus the score at baseline of the British Isles Lupus Assessment Group 2004 Index (BILAG-2004)

    Time frame: pre-dose and up to 52 weeks post the first dose

  3. Change from Baseline in Physician's Global Assessment (PGA) Score

    Change from baseline will be calculated as the score at each post-baseline visit minus the score at baseline of PGA score

    Time frame: pre-dose and up to 52 weeks post first dose

  4. Composite efficacy response rates

    Proportion of participants achieving the SLE Responder Index-4 (SRI-4) response

    Time frame: baseline and up to Week 52 post first dose

  5. Composite efficacy response rates

    Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)

    Time frame: baseline and up to Week 52 post first dose

  6. Composite efficacy response rates

    Proportion of participants achieving the Definition Of Remission In SLE (DORIS).

    Time frame: Baseline and up to Week 52 post first dose

  7. Change from baseline in SF-36 score

    Change from baseline in 36-Item Short-Form Health Survey (SF-36) score.

    Time frame: baseline and up to Week 52 post first dose

  8. Change from baseline in renal parameters

    Urine protein will be quantified from a 24-hour urine collection at each scheduled visit, expressed in grams per 24 hours (g/24h). Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline

    Time frame: Baseline and up to Week 52 post first dose

  9. Change from baseline in renal parameters

    Change from Baseline in Urine Protein-to-Creatinine Ratio (UPCR).Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline.

    Time frame: Baseline and up to Week 52 post first dose

  10. Change from baseline in renal parameters

    Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) by CKD-EPI;Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline.

    Time frame: baseline and up to Week 52 post first dose

  11. Change from baseline in renal parameters

    Proportion of participants with baseline proteinuria \>0.5 g/24h achieving proteinuria negativity.

    Time frame: Baseline and up to Week 52 post first dose

  12. Pharmacokinetic profiling

    Quantification of Target mRNA Expression Levels in Biological Samples via RT-qPCR.

    Time frame: Baseline and up to 24 weeks post first dose

  13. Pharmacokinetics measurement

    Bioanalytical Quantification of Cationic Lipids and Major Metabolites using LC/MS

    Time frame: baseline and up to 24 weeks post first dose

  14. Pharmacodynamic Profiling

    Serum concentrations of the TCE protein will be evaluated using a validated Enzyme-Linked Immunosorbent Assay (ELISA)

    Time frame: Baseline and up to 24 weeks post first dose

  15. Pharmacodynamic biomarkers

    Changes from baseline in serum IgG, IgM, IgA, anti-dsDNA antibodies, complement C3, and complement C4.

    Time frame: Baseline and up to 52 weeks post first dose

  16. Immunogenicity

    Percentage of participants who develop treatment-induced or treatment-enhanced ADAs and subsequent NAbs against ACG102 as determined by validated immunoassays.

    Time frame: Baseline and up to 52 weeks post first dose

  17. Immunogenicity

    Percentage of participants with detectable antibodies directed against the PEG component of the formulation, measured via validated serum assays.

    Time frame: Baseline and up to 52 weeks post first dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Aug 6, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749430
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Aug 6, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

qiubai li, archiater
Contact
liqiubai_hust@hust.edu.cn
027-85726808

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion